

# Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity & Clinical Trials Insight 2028

<https://marketpublishers.com/r/G2936AB9D18BEN.html>

Date: March 2023

Pages: 300

Price: US\$ 2,800.00 (Single User License)

ID: G2936AB9D18BEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity & Clinical Trials  
Insight 2028 Report Highlights:

First TIL Therapy Commercial Availability By 2024

TIL Therapy Future Market Opportunity Assessment: > USD 400 million

Global TIL Therapies Clinical Pipeline By Company, Indication & Phase

Insight On More Than 30 TIL Therapies In Pipeline

TIL Therapy Proprietary Technologies Insight By Companies

TIL Therapy By Cancer: Ongoing Clinical Trials & Trends

The field of cell therapy has witnessed rapid evolution over the past few years, with various innovative technologies being developed to target and treat different types of cancer. One such therapy is tumor infiltrating lymphocyte (TIL) therapy which involves extraction of TILs from a patient's tumor, expanding them in a lab and then infusing them back into the patient to target cancer cells. Emergence of such therapy opens an unexplored window of personalized therapy. With gathered curiosity from the pharmaceutical industry TIL therapy has created itself a secured market space in the cancer treatment landscape.

The TIL therapy market is expected to see significant growth in the coming years due to its potential to provide durable, long term responses in patients with advanced or metastatic cancers. Personalized medicine is one of the major drivers of the TIL therapy market as it enables the therapy to be tailored to the specific needs to each patient. Companies such as lovance Biotherapeutics and TILT Biotherapeutics are at the forefront of developing personalized TIL therapies, with lovance's lead candidate Lifileucel already collecting significant attention from regulatory bodies around the world.

Another factor driving the growth of TIL therapy market is the increasing prevalence of cancer worldwide. With cancer rates on the rise, there is a growing need for effective therapies that can provide long term remission or cure. TIL therapy has shown promise in providing durable responses in patients with advanced cancers, including melanoma and cervical cancer. Moreover, government regulations also play a crucial role in shaping the competitive landscape of TIL therapy market.

The FDA has granted Fast Track and Breakthrough Therapy designations to some TIL therapies in pipeline, expediting the regulatory process and allowing them to reach the market faster. This has led to an increase in investment in TIL therapy research and development by pharmaceutical and biotech companies, further fueling the market's growth. For instance, Lifileucel has bagged FDA RMAT (Regenerative Medicine Advanced therapy) designation, FDA BTA (Breakthrough Therapy Designation) for different cancer indications, increasing its anticipated arrival in the market.

The emergence of combination therapies is another trend that is expected to shape the competitive landscape of TIL therapy in the coming years. To create a wider market reach and more penetration, companies which adopt combination strategies gain an advantage of fashioning an already secured target patient population. lovance Biotherapeutics has adopted a similar approach by testing various combinations of Lifileucel with other immunotherapies in different cancer indications. This does not only expand Lifileucel's expected onset but the collaborative agreements done in order to start such combinational trials bring more investment to the company and ultimately increase their market share.

In terms of competition, the TIL therapy market is relatively nascent with only a handful of players currently in the space. However with the potential for significant growth in the market more companies are expected to enter the fray in the coming years. Currently, major players in the TIL therapy market include; lovance Biotherapeutics, TILT Biotherapeutics, Instill Bio, Achilles Therapeutics and others. These companies are

various stages of clinical development have demonstrated that their respective candidates have the potential to potentially lead the TIL therapy market.

For now, the arrival of first ever TIL therapy product is expected to enter the market by the end of 2023 or most by the beginning of 2024. Lifileucel is the most anticipated product in this emerging market as its clinical results in monotherapy or in combination with other immunotherapies have been the most widely acceptable. Furthermore, it can also be expected that after the approval of Lifileucel, as more companies enter the market, 1 more drug can bag its FDA approval in 5-6 years.

As this emerging market continues to grow, it is likely that more companies will enter the space leading to increased competition and innovation. TIL therapy market is poised for significant growth in the coming years, driven by various factors but mainly by the demand of novel therapies. As the technology evolves and manufacturing process becomes more scalable, TIL therapy has the potential to become a major player in the cancer treatment market landscape with expected market opportunity reach beyond US\$400 Million by 2028.

## Contents

### **1. TUMOR INFILTRATING LYMPHOCYTES (TIL): A BRIEF INTRODUCTION**

- 1.1 Overview
- 1.2 TIL History & Concept

### **2. EMERGENCE OF TUMOR INFILTRATING LYMPHOCYTES THERAPY**

- 2.1 Tumor Infiltrating Lymphocytes As Prognostic Biomarkers
- 2.2 Tumor Infiltrating Lymphocytes Therapy Combinational Approach

### **3. TUMOR INFILTRATING LYMPHOCYTES THERAPY APPROACHES BY CANCER: ONGOING CLINICAL TRIALS & TRENDS**

- 3.1 Melanoma
- 3.2 Colorectal Cancer
- 3.3 Gastrointestinal Cancers
- 3.4 Gastric Cancer
- 3.5 Pancreatic Cancer
- 3.6 Hepatocellular Carcinoma (Liver Cancer)
- 3.7 Lung Cancers
- 3.8 Non Small Cell Lung Cancer
- 3.9 Gynecological Carcinomas
- 3.10 Ovarian Cancer
- 3.11 Uterine/Endometrial Cancer
- 3.12 Cervical Cancer
- 3.13 Genitourinary Cancers
- 3.14 Bladder/Urothelial Carcinoma
- 3.15 Renal Cell Carcinoma (RCC)
- 3.16 Prostate Cancer
- 3.17 Head & Neck Cancer
- 3.18 Breast Cancer
- 3.19 Blood Cancer
- 3.20 Brain Tumors

### **4. GLOBAL TUMOUR INFILTRATING LYMPHOCYTE THERAPIES CLINICAL PIPELINE OVERVIEW**

- 4.1 Company
- 4.2 Country
- 4.3 By Indication
- 4.4 Patient Segment
- 4.5 By Phase

## **5. GLOBAL TUMOUR INFILTRATING LYMPHOCYTE THERAPIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 5.1 Preclinical
- 5.2 Clinical
- 5.3 Phase-I
- 5.4 Phase-I/II
- 5.5 Phase-II
- 5.6 Preregistration

## **6. TUMOR INFILTRATING LYMPHOCYTES THERAPY PROPRIETARY TECHNOLOGIES INSIGHT BY COMPANIES**

## **7. TUMOR INFILTRATING LYMPHOCYTES THERAPY MARKET TRENDS & DEVELOPMENT**

- 7.1 Market Collaborations
- 7.2 Clinical Outlook

## **8. GLOBAL TUMOR INFILTRATING LYMPHOCYTES THERAPY MARKET ANALYSIS**

- 8.1 Growing Frontier for Tumor Infiltrating Lymphocyte Therapy Market as Personalized Treatment
- 8.2 Current Market Scenario
- 8.3 Therapy Cost Analysis

## **9. TUMOR INFILTRATING LYMPHOCYTES THERAPY MARKET DYNAMICS**

- 9.1 Market Drivers
- 9.2 Market Challenges

## **10. TUMOR INFILTRATING LYMPHOCYTES THERAPY FUTURE MARKET**

## OUTLOOK

### 11. COMPETITIVE LANDSCAPE

- 11.1 Adaptimmune
- 11.2 AgonOx
- 11.3 Cellular Biomedicine Group
- 11.4 Cellular Therapeutics
- 11.5 GRIT Biotechnology
- 11.6 Hebei Senlang Biotechnology
- 11.7 ImmuneCyte
- 11.8 Instil Bio
- 11.9 Intima Bioscience
- 11.10 Iovance Biotherapeutics
- 11.11 Lyell Immunopharma
- 11.12 National Cancer Institute (USA)
- 11.13 National Institutes of Health (USA)
- 11.14 Nurix
- 11.15 Obsidian Therapeutics
- 11.16 OriginCell Therapeutics
- 11.17 RootPath
- 11.18 Shanghai Gencells Therapeutics
- 11.19 SQZ Biotech
- 11.20 Turnstone Biologics

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Procedure of Tumor Infiltrating Lymphocytes Therapy
- Figure 1-2: Evolution of Tumor Infiltrating Lymphocytes (TIL) Therapy
- Figure 2-1: Combinational Approaches In TILs For Different Cancer Indications
- Figure 3-1: Benefits of Tumor Infiltrating Lymphocytes (TIL) in Cancer
- Figure 3-2: Evaluation Of Tumor Infiltrating Lymphocytes in Solid Tumors
- Figure 3-3: Therapies Used in Combination with Tumor Infiltrating Lymphocytes Therapy
- Figure 3-4: Tumor Infiltrating Lymphocytes as Adjuvant Therapy of Melanoma
- Figure 3-5: Iovance Biotherapeutics – Melanoma - C-144-01 Trial - Study Initiation & Expected Completion Year
- Figure 3-6: Karolinska University Hospital – Melanoma - MAT02 Trial - Study Initiation & Expected Completion Year
- Figure 3-7: Role of Tumor Infiltrating Lymphocytes in Colorectal Cancer
- Figure 3-8: Colorectal Cancer - M.D. Anderson Cancer Center - MDA-TIL Trial - Study Initiation & Expected Completion Year
- Figure 3-9: Colorectal Cancer - NCI - TIL Trial - Study Initiation & Expected Completion Year
- Figure 3-10: Colorectal Cancer - University of Pittsburgh - TIL Trial - Study Initiation & Expected Completion Year
- Figure 3-11: Global – Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
- Figure 3-12: Global – Number of Deaths by Leading Gastrointestinal Cancer, 2020
- Figure 3-13: Tumor Infiltrating lymphocytes In Management Of Gastrointestinal Cancer
- Figure 3-14: TILs Responsible For Microsatellite Instability In Gastric Cancer
- Figure 3-15: Gastric Cancer - University of Pittsburgh -TIL Trial - Study Initiation & Expected Completion Year
- Figure 3-16: Gastric Cancer - Fujian Medical University - Study Initiation & Expected Completion Year
- Figure 3-17: Gastric Cancer - Intima Biosciences - Study Initiation & Expected Completion Year
- Figure 3-18: Pancreatic Cancer - Juncell Therapeutics - Study Initiation & Expected Completion Year
- Figure 3-19: Pancreatic Cancer - Shanghai Biomed-Union Biotechnology - Study Initiation & Expected Completion Year
- Figure 3-20: Infiltrated T-Cells Assisting the Prognosis of Liver Cancer

Figure 3-21: Hepatocellular Carcinoma - Guangdong Zhaotai InVivo Biomedicine - Study Initiation & Expected Completion Year

Figure 3-22: Hepatocellular Carcinoma - Shanghai Juncell Therapeutics - Study Initiation & Expected Completion Year

Figure 3-23: TIL Therapy for Lung Cancer

Figure 3-24: Type of Infiltrated T-Cells in Lung Cancer

Figure 3-25: Lung Cancer - Guangdong Zhaotai InVivo Biomedicine - Study Initiation & Expected Completion Year

Figure 3-26: Role Of Tumor Infiltrating Lymphocytes In Non-Small Cell Lung Cancer

Figure 3-27: Non-Small Cell Lung Cancer - Iovance Biotherapeutics - Lifileucel/LN-145 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-28: Non-Small Cell Lung Cancer - Iovance Biotherapeutics – LN-145 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-29: Non-Small Cell Lung Cancer - Iovance Biotherapeutics – IOV-4001 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-30: Non-Small Cell Lung Cancer - Cellular Biomedicine - C-TIL051 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-31: Non-Small Cell Lung Cancer - Moffitt Cancer and Research Institute - Study Initiation & Expected Completion Year

Figure 3-32: Non-Small Cell Lung Cancer - Origin Cell Therapeutics - Study Initiation & Expected Completion Year

Figure 3-33: Non-Small Cell Lung Cancer - Intima Biosciences - CISH Inactivated TILs - Study Initiation & Expected Completion Year

Figure 3-34: Non-Small Cell Lung Cancer - BlueHorse Therapeutics – LM103 Injection - Study Initiation & Expected Completion Year

Figure 3-35: Non-Small Cell Lung Cancer - Lyell Immunopharma – LYL-845 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-36: Non-Small Cell Lung Cancer - Instil Bio – ITIL-306 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-37: Non-Small Cell Lung Cancer - Micorbio Co Ltd – MS-20 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-38: Non-Small Cell Lung Cancer - NCI –TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-39: Global – Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020

Figure 3-40: Global – Number of Deaths by Leading Gynecological Cancer, 2020

Figure 3-41: Role of Tumor Infiltrating Lymphocytes in Various Gynecological Cancer

Figure 3-42: Gynecological Cancer - Junshi Therapeutics –TIL Therapy - Study Initiation & Expected Completion Year



Figure 3-43: Gynecological Cancer - Junshi Therapeutics – GC203 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-44: Gynecological Cancer - Junshi Therapeutics – GC201 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-45: TILs Therapy for Ovarian Cancer

Figure 3-46: Tumor Infiltrating Lymphocytes In Prognosis Of Ovarian Cancer

Figure 3-47: Ovarian Cancer – NCI - TIL Trial - Study Initiation & Expected Completion Year

Figure 3-48: Ovarian Cancer – Herlev Hospital - Relatlimab-Nivolumab & TIL Trial - Study Initiation & Expected Completion Year

Figure 3-49: Ovarian Cancer – Iovance Biotherapeutics – LN-145 & Ln-145-S1 TIL Trial - Study Initiation & Expected Completion Year

Figure 3-50: Ovarian Cancer Targeting Tumor Infiltrating Lymphocytes Therapies in Clinical Trials

Figure 3-51: Tumor Infiltrating Lymphocytes In Prognosis Of Endometrial Cancer

Figure 3-52: Endometrial Cancer – Nurix Therapeutics – DeTIL-0255 TIL Therapy – Study Initiation & Expected Completion Year

Figure 3-53: TILs With Prognostic Significance In Cervical Cancer

Figure 3-54: Cervical Cancer – Fudan University – C-TIL052A Injection – Study Initiation & Expected Completion Year

Figure 3-55: Cervical Cancer – OriginCell Therapeutics – TIL Therapy – Study Initiation & Expected Completion Year

Figure 3-56: Cervical Cancer – Senlang Biotechnology – SL22P TIL Therapy – Study Initiation & Expected Completion Year

Figure 3-57: Cervical Cancer – Iovance Biotherapeutics – LN145 TIL Therapy – Study Initiation & Expected Completion Year

Figure 3-58: Global – Number of Newly Diagnosed Cases of Leading Genitourinary Cancer, 2020

Figure 3-59: Global – Number of Deaths by Leading Genitourinary Cancer, 2020

Figure 3-60: Infiltrated T-cells in Urothelial Cancer

Figure 3-61: Bladder Cancer - Sheba Medical Center – TIL Therapy – Study Initiation & Expected Completion Year

Figure 3-62: Infiltrated T-Cells in Renal Cell Carcinoma

Figure 3-63: Renal Cell Carcinoma – Instill Bio – ITIL-306 TIL Therapy – Study Initiation & Expected Completion Year

Figure 3-64: TIL Therapy For Prostate Cancer

Figure 3-65: TILs In Prognosis Of Prostate Cancer

Figure 3-66: Global – Newly Diagnosed Cases & Deaths related to Head & Neck Cancer, 2020

Figure 3-67: TIL Therapy Procedure For Targeting Head & Neck Cancer

Figure 3-68: TILs In Prognosis Of Head & Neck Cancer

Figure 3-69: Head & neck Cancer – LN-145 TIL Therapy – Study Initiation & Estimated Completion Year

Figure 3-70: Head & neck Cancer – TIL Therapy – Study Initiation & Estimated Completion Year

Figure 3-71: Global – Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020

Figure 3-72: Infiltrating T Cells Assisting In Prognosis Of Breast Cancer

Figure 3-73: TIL Therapy Procedure for Breast Cancer

Figure 3-74: Evaluation of TILs for Breast Cancer

Figure 3-75: Breast Cancer – Iovance Biotherapeutics – TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-76: Breast Cancer – SOLTI Breast Cancer Research Group – NUMARZU-001 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-77: Breast Cancer – Juncell Therapeutics– GC 101 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-78: Breast Cancer – The Affiliated Hospital of Qingdao University – HS-IT 101 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-79: Breast Cancer – Turnstone Biologics – TBio-4101 TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-80: Global – Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020

Figure 3-81: Global – Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020

Figure 3-82: Infiltration of TILs In Leukemia

Figure 3-83: Tumor Infiltrating Lymphocytes Therapy Procedure in Leukemia

Figure 3-84: Type of Beneficial Infiltrating Cells in Leukemia

Figure 3-85: Global – Newly Diagnosed Cases & Deaths related to Brain Cancer, 2020

Figure 3-86: Role of Tumor Infiltrating Lymphocytes Therapy in Brain Tumor

Figure 3-87: Infiltrated T-Cells in Brain Tumor

Figure 3-88: Brain Cancer - Senlang Biotechnology – TIL Therapy - Study Initiation & Expected Completion Year

Figure 3-89: Brain Cancer - Juncell Therapeutics – TIL Therapy - Study Initiation & Expected Completion Year

Figure 4-1: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Company, 2023 till 2028

Figure 4-2: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Country, 2023 till 2028

Figure 4-3: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Indicating, 2023 till 2028

Figure 4-4: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Patient Segment, 2023 till 2028

Figure 4-5: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Phase, 2023 till 2028

Figure 6-1: Instil Bio – Tumor Processing Method Releases & Preserves All Of The TILs From Tumor Samples

Figure 6-2: Instil Bio – ITIL-168 – Manufacturing & Treatment Process

Figure 6-3: Iovance Biotherapeutics – Steps For Gen 2 TIL Proprietary Technology

Figure 6-4: Iovance Biotherapeutics - Streamlined 22-day GMP Manufacturing Process

Figure 6-5: Design Of Nurix DEL Collection

Figure 6-6: Key Features Of DELigase Platform

Figure 6-7: Nurix's DNA Encoded Library In Drug Development

Figure 6-8: INTASYL Mechanism Of Action

Figure 6-9: PELEUS Three-Step Process

Figure 6-10: Current VELOS Manufacturing Process

Figure 6-11: TILT-123 Viral Construct

Figure 6-12: TILI-123 Mode Of Action

Figure 6-13: Selected TIL Approach

Figure 6-14: Virus Plus TIL Therapy

Figure 6-15: Structure Of A TALEN

Figure 6-16: TALEN Gene Editing

Figure 6-17: Various Gene Editing Mechanisms Enabled By TALEN

Figure 6-18: TALEN Technology Permits High Specific Cleavage

Figure 6-19: CYTODRIVE Platform

Figure 6-20: Novoleucel Steps Involved

Figure 6-21: TiL Manufacturing Process

Figure 8-1: US – Minimum & Maximum Cost of Tumor Infiltrating Lymphocytes Therapy Treatment, October'2020

Figure 8-2: Proleukin – Cost of Single Powder for Injection, Single Day & Full Treatment (US\$), October'2020

Figure 8-3: Cyclophosphamide – Cost of various Supplies of Powder for Injection (US\$), October'2020

Figure 8-4: Cyclophosphamide – Price of 2.5ml Supply & Price per ml of Intravenous Solution (US\$), October'2020

Figure 8-5: Cyclophosphamide – Average Cost of Single Day & Full Treatment (US\$), October'2020

Figure 8-6: Fludarabine – Average Cost of Single Day & Full Treatment (US\$), October'2020

Figure 9-1: Driving Forces for Tumor Infiltrating Therapy Market

Figure 9-2: Factors Challenging The Market Growth Of TIL Therapy

Figure 10-1: Global - Global Tumor Infiltrating Lymphocytes Therapy Market Forecast (US\$ Million), 2023 - 2028

Figure 10-2: Global - Future Drivers for Tumor Infiltrating Lymphocyte Therapy Market

Figure 10-3: Global – Future Regional Powers for Tumor Infiltrating Lymphocyte Therapy Market

## I would like to order

Product name: Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/G2936AB9D18BEN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2936AB9D18BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

